Curis Lifesciences Ltd

AI
Curis Lifescien. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Curis Lifesciences Ltd

₹ 176 -4.62%
23 Oct - close price
curisls.com NSE - SME: CURIS
About

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]

Key Points

Business Overview:[1][2]
CLSL is a WHO-GMP certified pharma company based in Ahmedabad, India. The co. provides healthcare solutions with loan licensing and also contract manufacturing and offers pharma products formulated from solid and liquid forms to deliver adherence to every therapeutic category. Its offerings also include sterile and non-sterile products. The company exports to 10+ countries and has 18k+ customers

Website NSE - ST
  • Market Cap ₹ 143 Cr.
  • Current Price ₹ 176
  • High / Low ₹ 235 / 83.6
  • Stock P/E 20.6
  • Book Value ₹ 58.6
  • Dividend Yield 0.00 %
  • ROCE 21.2 %
  • ROE 21.7 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Working capital days have increased from 123 days to 232 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty SME Emerge

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2024 Mar 2025 Sep 2025 Mar 2026
15.90 34.36 27.91 32.72
12.09 27.43 21.92 27.58
Operating Profit 3.81 6.93 5.99 5.14
OPM % 23.96% 20.17% 21.46% 15.71%
-0.02 0.05 0.00 0.27
Interest 0.50 0.61 0.43 0.71
Depreciation 0.34 0.34 0.34 0.35
Profit before tax 2.95 6.03 5.22 4.35
Tax % 25.42% 33.67% 19.35% 37.70%
2.20 4.00 4.21 2.71
EPS in Rs 4.00 6.74 7.09 3.35
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
23.70 35.21 35.13 50.26 60.63
20.12 31.95 26.74 39.51 49.50
Operating Profit 3.58 3.26 8.39 10.75 11.13
OPM % 15.11% 9.26% 23.88% 21.39% 18.36%
0.02 0.34 0.31 0.02 0.27
Interest 1.62 1.33 0.85 1.11 1.14
Depreciation 0.75 0.73 0.68 0.67 0.70
Profit before tax 1.23 1.54 7.17 8.99 9.56
Tax % 59.35% 20.13% 32.22% 30.92% 27.62%
0.49 1.23 4.87 6.21 6.92
EPS in Rs 0.89 2.24 8.85 10.46 8.56
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 20%
TTM: 21%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 78%
TTM: 12%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 39%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.50 0.50 0.50 5.93 8.08
Reserves -1.40 -0.18 5.37 10.58 39.27
17.62 16.19 17.09 15.61 21.59
10.68 13.16 10.91 10.48 12.58
Total Liabilities 27.40 29.67 33.87 42.60 81.52
12.33 12.20 11.59 10.99 10.78
CWIP 0.00 0.00 0.00 0.02 1.33
Investments 0.01 0.01 0.01 0.01 0.01
15.06 17.46 22.27 31.58 69.40
Total Assets 27.40 29.67 33.87 42.60 81.52

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
4.95 3.35 0.28 -2.03 -16.42
-0.37 -0.55 -0.06 -0.02 -1.59
-4.58 -2.76 0.05 1.94 20.87
Net Cash Flow -0.01 0.04 0.27 -0.11 2.86
Free Cash Flow 4.56 2.77 0.21 -2.06 -18.24
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 138% 103% 3% -5% -127%

Ratios

Standalone / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 96.10 98.17 104.94 55.05 67.55
Inventory Days 208.46 114.92 273.22 347.26 693.60
Days Payable 359.58 262.67 210.40 113.24 166.33
Cash Conversion Cycle -55.01 -49.58 167.75 289.07 594.81
Working Capital Days -16.02 -20.84 36.26 99.27 232.20
ROCE % 17.21% 40.64% 36.64% 21.20%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Export Revenue Share
%

Log in to view insights

Please log in to see hidden values.

Login
Tablets Capacity Utilization
%
Total Number of Customers (Loan License, Contract Manufacturing and Direct Export)
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Nov 2025Mar 2026Sep 2026
68.03% 68.03% 68.03%
2.93% 1.19% 1.05%
10.86% 5.80% 4.63%
18.17% 24.98% 26.29%
No. of Shareholders 542340315

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls